Subscribe

Tibet Rhodiola Pharmaceutical Holding Co. Class A (600211.SS)

CNY40.07 +0.77 (+1.96%)
CN SHH Healthcare Medical - Pharmaceuticals
Address Lhasa Economic and Technological Development Zone 850000
Lhasa, XJ, CN
CEO Yuan Dong Guo
Website xzyy.cn
IPO 1999-07-21
ISIN CNE000000ZW7

Explore sections of this company profile

Description

Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-release tablets; and oxygen rhodiola rosea moisturizing essence, secret recipe fragrance powder packet, rhodiola rosea, and Yuan Yang rhodiola rosea moisturizing essence products. In addition, the company offers biopharmaceuticals, traditional Chinese medicine, and chemical drugs for various fields, such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines. The company was founded in 1999 and is headquartered in Lhasa, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY40.07 +0.77 (+1.96%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.25
Float Shares
265.03M
Free Float %
82.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+2.04% -2.85% -4.75% -9.49% -8.85% -9.42% +4.05% -14.32% -26.25% +70.30% +355.56%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
40.07
DCF (Unlevered) 196.18 +389.6%
DCF (Levered) 201.38 +402.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2024-11 Change
Strong Buy 1 0
Buy 2 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
5.63
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Pharmaceuticals: +7.8%
    +5.1% Q1'26: +1.6% (vs Q1'25)
  • ✗
    EPS growth Medical - Pharmaceuticals: +20.2%
    -10.7% Q1'26: +10.7% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    +28.4% Q1'26: +53.3% (vs Q1'25)
  • ✓
    EBIT margin Medical - Pharmaceuticals: +6.8%
    +31.3% ★ Q1'26: +29.5% (vs Q1'25)
  • ✓
    ROIC Medical - Pharmaceuticals: +6.1%
    +53.3% ★ Q1'26: +52.0% (vs Q1'25)
  • ✓
    Share dilution Medical - Pharmaceuticals: +0.0%
    -0.1% ★ Q1'26: +0.5% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    0.84× ★ Q1'26: 1.24× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.30) × ERP
WACC = 94% × Ke + 6% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 196.18 Current price: 40.07
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
Revenue
1.38B
est: 1.38B (+0.5%)
796.81M
est: 759.00M (+5.0%)
915.63M
est: 1.01B (-9.6%)
1.03B
est: 1.03B (-0.4%)
1.26B
est: 1.38B (-9.0%)
1.37B
est: 1.45B (-5.3%)
2.14B
est: 1.84B (+16.3%)
2.55B
est: 2.20B (+16.0%)
3.13B
est: 3.11B (+0.8%)
2.81B
est: 3.81B (-26.3%)
2.95B
est: 4.64B (-36.4%)
4.83B
4.83B – 4.83B
+4.0% YoY
EBITDA
126.39M
est: 455.03M (-72.2%)
292.18M
est: 251.00M (+16.4%)
357.27M
est: 334.99M (+6.6%)
321.24M
est: 341.28M (-5.9%)
430.50M
est: 456.36M (-5.7%)
548.99M
est: 479.47M (+14.5%)
340.63M
est: 608.25M (-44.0%)
547.41M
est: 728.41M (-24.8%)
978.19M
est: 1.03B (-4.8%)
1.24B
est: 2.14B (-42.4%)
1.00B
est: 2.61B (-61.6%)
2.72B
2.72B – 2.72B
+4.0% YoY
EBIT
113.91M
est: 408.29M (-72.1%)
236.58M
est: 225.21M (+5.0%)
280.07M
est: 300.58M (-6.8%)
244.71M
est: 306.21M (-20.1%)
353.72M
est: 409.47M (-13.6%)
471.37M
est: 430.21M (+9.6%)
259.18M
est: 545.76M (-52.5%)
478.17M
est: 653.57M (-26.8%)
910.15M
est: 922.27M (-1.3%)
1.16B
est: 2.07B (-44.0%)
924.70M
est: 2.53B (-63.4%)
2.63B
2.63B – 2.63B
+4.0% YoY
Net Income
91.64M
est: 101.00M (-9.3%)
198.29M
est: 210.85M (-6.0%)
229.65M
est: 217.94M (+5.4%)
215.61M
est: 299.45M (-28.0%)
312.32M
est: 352.60M (-11.4%)
418.10M
est: 394.42M (+6.0%)
208.94M
est: 461.40M (-54.7%)
369.84M
est: 558.14M (-33.7%)
800.91M
est: 719.38M (+11.3%)
1.05B
est: 885.14M (+18.8%)
937.93M
est: 1.06B (-11.8%)
—
— – —
-100.0% YoY
SGA
360.84M
est: 807.70M (-55.3%)
400.89M
est: 445.53M (-10.0%)
423.46M
est: 594.62M (-28.8%)
539.20M
est: 605.78M (-11.0%)
681.87M
est: 810.05M (-15.8%)
747.78M
est: 851.08M (-12.1%)
1.25B
est: 1.08B (+16.2%)
1.54B
est: 1.29B (+19.2%)
1.88B
est: 1.82B (+3.1%)
1.68B
est: 2.26B (-25.3%)
1.68B
est: 2.75B (-38.7%)
2.86B
2.86B – 2.86B
+4.0% YoY
EPS
0.35
est: 0.31 (+11.8%)
0.75
est: 0.65 (+14.7%)
0.75
est: 0.68 (+11.0%)
0.66
est: 0.93 (-28.9%)
0.96
est: 1.09 (-12.2%)
1.30
est: 1.22 (+6.3%)
0.65
est: 1.43 (-54.6%)
1.15
est: 1.73 (-33.6%)
2.48
est: 2.23 (+11.2%)
3.26
est: 2.75 (+18.7%)
2.91
est: 3.30 (-11.8%)
—
— – —
-100.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 5/5 5/5 5/5 2/5 2/5 2/5
2026-05-28 A- 4/5 5/5 5/5 5/5 2/5 2/5 2/5
2026-05-27 A- 4/5 4/5 5/5 5/5 2/5 2/5 2/5
2026-05-26 A- 4/5 4/5 5/5 5/5 2/5 2/5 2/5
2026-05-25 A- 4/5 4/5 5/5 5/5 2/5 2/5 2/5
2026-05-22 A- 4/5 4/5 5/5 5/5 2/5 2/5 2/5
2026-05-21 A- 4/5 4/5 5/5 5/5 2/5 2/5 2/5
2026-05-20 A- 4/5 4/5 5/5 5/5 2/5 2/5 2/5
2026-05-19 A- 4/5 4/5 5/5 5/5 2/5 2/5 2/5
2026-05-18 A- 4/5 4/5 5/5 5/5 2/5 2/5 2/5
2026-05-15 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-05-14 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-05-13 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-05-12 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-05-11 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-05-08 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-05-07 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-05-06 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-04-30 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-04-29 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-04-28 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-04-27 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-04-24 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-04-23 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-22 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-21 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-20 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-17 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-16 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.34B
OE per share TTM
4.15
Owner's Yield
10.77%
Maintenance CapEx ratio
0.21%
Maint CapEx / Avg PPE
22.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 19 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.01% 31.9K 0.44%
2 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.00% 448.6K 0.06%
3 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 285.7K 0.39%
4 Dimensional - Emerging Markets High Profitability ETF DEHP 0.00% 8.2K 0.44%
5 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 125.9K 0.29%
6 Vanguard FTSE Emerging Markets Shares ETF VGE.AX 0.00% 14.9K 0.48%
7 Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO 0.00% 33.7K 0.26%
8 Vanguard FTSE Emerging Markets ETF VWO 0.00% 1.66M 0.06%
9 Dimensional World ex U.S. Core Equity 2 ETF DFAX 0.00% 121.7K 0.28%
10 Vanguard ESG International Stock ETF VSGX 0.00% 19.7K 0.10%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
1.38M
Shares Outstanding
322.32M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Jun Chen Financial Director & Accounting Supervisor — male
Lan Liu Deputy GM & Secretary of the Board — female
Yong Guo Yuan Deputy General Manager — male
Yuan Dong Guo GM & Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals